compound introduction
JHDM-IN-1 (Compound 1) is a Jumonji C domain-containing HDMs ( JHDM ) inhibitor with IC 50 s of 3.4, 4.3, 5.9, 10 and 43 μM against JMJD2C, JMJD2A, JMJD2E, PHF8 and JMJD3, respectively In Vitro JHDM-IN-1 (Compound 1) also inhibits FIH, PHD3, PHD1, PHD2 and LSD1 with IC 50 s of 22, 31, 54, 83 and 620 μM, respectively. JHDM-IN-1 (0-100 μM) does not inhibit KYSE150 cell growth after treatment for 48 h. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 3.4 μM (JMJD2C), 4.3 μM (JMJD2A), 5.9 μM (JMJD2E), 10 μM (PHF8), 22 μM (FIH), 31 μM (PHD3), 43 μM (JMJD3), 54 μM (PHD1), 83 μM (PHD2), 620 μM (LSD1)
